Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, February 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 249 articles:
HTML format


 

Single Articles

  1. WANG H, Liu J, Lou Y, Liu Y, et al
    Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis.
    Sci Rep. 2024;14:2782.
    PubMed    
    Abstract available

  2. LOTAN Y, Agarwal P, Black P, Dickstein R, et al
    Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
    Urol Oncol. 2024 Feb 1:S1078-1439(24)00020-6. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  3. YU J, Cai L, Chen C, Zou Y, et al
    A novel predict method for muscular invasion of bladder cancer based on 3D mp-MRI feature fusion.
    Phys Med Biol. 2024 Feb 2. doi: 10.1088/1361-6560.
    PubMed    
    Abstract available

  4. ZHAO ZY, Cao Y, Wang HL, Liu LY, et al
    A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer.
    Cancer Biomark. 2024 Jan 8. doi: 10.3233/CBM-230216.
    PubMed    
    Abstract available

  5. SEGEL JE, Wong WG, Kaag M, Joshi M, et al
    Relationship Between Availability of Urologists and Primary Care Providers and Stage of Diagnosis for Invasive Urinary Bladder Cancer.
    Urol Pract. 2024 Jan 15:101097UPJ0000000000000503.
    PubMed    
    Abstract available

  6. BOSTANCI E, Kirkik D, Kalkanli Tas S, Uyeturk U, et al
    Genetic insights into bladder cancer: the impact of SIRT1 gene polymorphism.
    Nucleosides Nucleotides Nucleic Acids. 2024.
    PubMed    
    Abstract available

  7. WEI Z, Liu H, Xv Y, Liao F, et al
    Development and validation of a CT-based deep learning radiomics nomogram to predict muscle invasion in bladder cancer.
    Heliyon. 2024;10:e24878.
    PubMed    
    Abstract available

  8. YU J, Ge S
    PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells.
    Cytotechnology. 2024;76:85-96.
    PubMed    
    Abstract available

  9. MONSHAUGEN I, Luna L, Rhodes J, Kristiansen FIS, et al
    Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer.
    Front Oncol. 2024;13:1334112.
    PubMed    
    Abstract available

  10. BLACK PC, Eigl BJ
    The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast.
    Adv Ther. 2024 Feb 2. doi: 10.1007/s12325-023-02763.
    PubMed    


  11. LOBO N, Duan Z, Sood A, Tan WS, et al
    Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?
    Eur Urol Oncol. 2024 Jan 31:S2588-9311(24)00036.
    PubMed    
    Abstract available

  12. PORRECA A, Di Nicola M, Lucarelli G, Dorin VM, et al
    Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database.
    Urol Oncol. 2024 Jan 31:S1078-1439(24)00003.
    PubMed    
    Abstract available

  13. ABE M, Hiraki H, Tsuyukubo T, Ono S, et al
    The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer.
    J Mol Diagn. 2024 Jan 30:S1525-1578(24)00012.
    PubMed    
    Abstract available

  14. XU Y, Sun X, Liu G, Li H, et al
    Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Front Immunol. 2024;14:1301157.
    PubMed    
    Abstract available

  15. YANG H, Ma L, Deng W, Fu B, et al
    Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor.
    Front Immunol. 2024;14:1301945.
    PubMed    
    Abstract available

  16. INTERNATIONAL EM
    Retracted: Preoperative Nutritional Risk Assessment for Predicting Complications after Radical Cystectomy plus Urinary Diversion for Bladder Cancer.
    Emerg Med Int. 2024;2024:9849523.
    PubMed    
    Abstract available

  17. NARDELLI C, Aveta A, Pandolfo SD, Tripodi L, et al
    Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample.
    Eur Urol Open Sci. 2023;59:18-26.
    PubMed    
    Abstract available

  18. CHEN S, Sun G, Chen X, Salgado T, et al
    Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
    BMC Urol. 2024;24:25.
    PubMed    
    Abstract available

  19. GROBET-JEANDIN E, Lenfant L, Pinar U, Parra J, et al
    Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases.
    Nat Rev Urol. 2024 Jan 31. doi: 10.1038/s41585-023-00842.
    PubMed    
    Abstract available

  20. MARIAPPAN P, Johnston A, Trail M, Hamid S, et al
    Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2024 Jan 30:S2588-9311(24)00037.
    PubMed    
    Abstract available

  21. LV HX, Wang D, Zhou FH
    Definition of the prognosis value of urine extracellular vesicles ZNF540 in bladder cancer based on GEO database.
    Asian J Surg. 2024 Jan 30:S1015-9584(24)00109.
    PubMed    


  22. LI F, Zhang H, Huang Y, Li D, et al
    Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.
    Drug Resist Updat. 2024;73:101059.
    PubMed    
    Abstract available

  23. LI P, Wang W, Zhu B, Wang Y, et al
    PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer.
    Environ Toxicol. 2024 Jan 31. doi: 10.1002/tox.24153.
    PubMed    
    Abstract available

  24. YAN Q, Zeng P, Huang S, Tan C, et al
    [RBMX overexpression inhibits proliferation, migration, invasion and glycolysis of human bladder cancer cells by downregulating PKM2].
    Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:9-16.
    PubMed    
    Abstract available

  25. DONG L, Feng M, Kuczler MD, Horie K, et al
    Tumour tissue-derived small extracellular vesicles reflect molecular subtypes of bladder cancer.
    J Extracell Vesicles. 2024;13:e12402.
    PubMed    
    Abstract available

  26. LIU Z, Du D, Zhang S
    Integrated bioinformatics analysis identifies a Ferroptosis-related gene signature as prognosis model and potential therapeutic target of bladder cancer.
    Toxicol Res (Camb). 2024;13:tfae010.
    PubMed    
    Abstract available

  27. WANG J, Tan J, Zhang Y, Zhou L, et al
    circCD2AP promotes epithelial mesenchymal transition and stemness in bladder cancer by regulating FOXQ1/USP21 axis.
    iScience. 2023;27:108447.
    PubMed    
    Abstract available

  28. BAHLBURG H, Reicherz A, Reike M, Bach P, et al
    A prospective evaluation of quality of life, psychosocial distress, and functional outcomes two years after radical cystectomy and urinary diversion in 842 German bladder cancer patients.
    J Cancer Surviv. 2024 Jan 30. doi: 10.1007/s11764-024-01535.
    PubMed    
    Abstract available

  29. DEMIR R, Koc S, Ozturk DG, Bilir S, et al
    Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer.
    Sci Rep. 2024;14:2488.
    PubMed    
    Abstract available

  30. IIDA K, Naiki T, Etani T, Nagai T, et al
    Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
    Sci Rep. 2024;14:2520.
    PubMed    
    Abstract available

  31. MISHRA P, Jiongming L, Jianhe L, Kewei F, et al
    Prostate Cancer among Patients Undergoing Radical Cystoprostatectomy for Bladder Cancer in the Department of Urology in a Tertiary Care Centre.
    JNMA J Nepal Med Assoc. 2023;61:782-786.
    PubMed    
    Abstract available

  32. CHEN ZL, Jia KP, Zheng Y, Zhang N, et al
    Electrocardiographic characteristics of bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy.
    Ann Noninvasive Electrocardiol. 2024;29:e13107.
    PubMed    
    Abstract available

  33. NIE Z, Guo N, Peng Y, Gao Y, et al
    Author Correction: Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.
    Sci Rep. 2024;14:2369.
    PubMed    


  34. ZHU S, Zhao H
    Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.
    Front Pharmacol. 2024;14:1326627.
    PubMed    
    Abstract available

  35. SCHNEIDER AK, Domingos-Pereira S, Cesson V, Polak L, et al
    Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
    Front Immunol. 2024;14:1335326.
    PubMed    
    Abstract available

  36. JIANG S, Yang X, Lin Y, Liu Y, et al
    Unveiling Anoikis-related genes: A breakthrough in the prognosis of bladder cancer.
    J Gene Med. 2024;26:e3651.
    PubMed    
    Abstract available

  37. SU H, Liu Z, Zhang C, Deng Z, et al
    Exploration of the prognostic effect of costimulatory genes in bladder cancer.
    J Gene Med. 2024;26:e3655.
    PubMed    
    Abstract available

  38. HUANG WQ, Zhang L, Fu S, Shi GZ, et al
    [Mesonephric-like adenocarcinoma of the female urinary bladder associated with endometriosis: report of a case].
    Zhonghua Bing Li Xue Za Zhi. 2024;53:201-203.
    PubMed    


  39. ZHU C, Fang X, Liu X, Jiang C, et al
    Squalene monooxygenase facilitates bladder cancer development in part by regulating PCNA.
    Biochim Biophys Acta Mol Cell Res. 2024;1871:119681.
    PubMed    
    Abstract available

  40. BAUST JM, Corcoran A, Robilotto A, Katz AE, et al
    Evaluation of a New Cystoscopic Cryocatheter and Method for the In Situ Destruction of Bladder Cancer: Preliminary In vivo Study.
    J Endourol. 2024 Jan 27. doi: 10.1089/end.2023.0635.
    PubMed    
    Abstract available

  41. SU Y, Chen H, Yao L, Dai H, et al
    The relationship between the expression of lncRNA MALAT1 and clinical features and prognosis in bladder cancer: A meta-analysis.
    Cell Mol Biol (Noisy-le-grand). 2023;69:166-171.
    PubMed    
    Abstract available

  42. LUMKUL L, Jantaree P, Jaisamak K, Wongkummool W, et al
    Combinatorial Gene Expression Profiling of Serum HULC, HOTAIR, and UCA1 lncRNAs to Differentiate Hepatocellular Carcinoma from Liver Diseases: A Systematic Review and Meta-Analysis.
    Int J Mol Sci. 2024;25:1258.
    PubMed    
    Abstract available

  43. JO A, Joh HM, Bae JH, Kim SJ, et al
    Plasma-Activated Media Produced by a Microwave-Excited Atmospheric Pressure Plasma Jet Is Effective against Cisplatin-Resistant Human Bladder Cancer Cells In Vitro.
    Int J Mol Sci. 2024;25:1249.
    PubMed    
    Abstract available

  44. MAO Q, Liu H, Wu J, Cui Y, et al
    Prognostic significance of lncRNA AL354919.2 in bladder cancer.
    Asian J Surg. 2024 Jan 25:S1015-9584(24)00099.
    PubMed    


  45. LIN YH, Tsai HY, Juang HH
    Re: Christopher D. Gaffney, Andrew Katims, Neeta D'Souza, Marc A. Bjurlin, Richard S. Matulewicz. Bladder Cancer Carcinogens: Opportunities for Risk Reduction. Eur Urol Focus 2023;9:575-8.
    Eur Urol Focus. 2024 Jan 25:S2405-4569(24)00006.
    PubMed    


  46. SORIA F, Gontero P
    Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG)
    Eur Urol Focus. 2024 Jan 25:S2405-4569(24)00004.
    PubMed    


  47. ZHANG HP, Liang RX, Lin XY, Xue ES, et al
    Application of contrast-enhanced ultrasound in diagnosis and grading of bladder urothelial carcinoma.
    BMC Med Imaging. 2024;24:26.
    PubMed    
    Abstract available

  48. MANNEH KOPP R, Galanternik F, Schutz FA, Kater F, et al
    Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma.
    JCO Glob Oncol. 2024;10:e2300244.
    PubMed    
    Abstract available

  49. LIU Y, Qi P, Chen G, Lang Z, et al
    Nanoreactor based on single-atom nanoenzymes promotes ferroptosis for cancer immunotherapy.
    Biomater Adv. 2024;157:213758.
    PubMed    
    Abstract available

  50. REN Y, Liu T, Li S, Ma X, et al
    An iodine?labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
    Int J Pharm. 2024;651:123756.
    PubMed    
    Abstract available

  51. WANG CS, Lee YC, Jhan JH, Li WM, et al
    MicroRNA-299-3p inhibits cell proliferation, motility, invasion and angiogenesis via VEGFA in upper tract urothelial carcinoma.
    J Gene Med. 2024;26:e3616.
    PubMed    
    Abstract available

  52. SUN Y, Lu Z, Taylor JA, Au JLS, et al
    Quantitative image analysis of intracellular protein translocation in 3-dimensional tissues for pharmacodynamic studies of immunogenic cell death.
    J Control Release. 2024;365:89-100.
    PubMed    
    Abstract available

  53. KLEMM J, Laukhtina E, Shariat SF
    Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients.
    Nat Rev Clin Oncol. 2024;21:87-88.
    PubMed    


  54. RICCHETTI G, Grimaldi A, Agricola E, Slavich M, et al
    Cardiac metastasis from urothelial carcinoma: a stealthy precursor.
    Eur Heart J Cardiovasc Imaging. 2024;25:e92.
    PubMed    


  55. WEI W, Wu D, Zhang Z, Liu J, et al
    Comparison of DNA methylation and cytology tests in urine to detect upper tract urothelial carcinoma: A paired-design diagnostic study.
    Am J Clin Pathol. 2024;161:115-121.
    PubMed    
    Abstract available

  56. BANDEIRA M, Dourado E, Lopes F, Tenazinha C, et al
    Reactive arthritis as a rare complication of intravesical bacillus Calmette-Guerin treatment: Report of two cases.
    Int J Rheum Dis. 2024;27:e14862.
    PubMed    
    Abstract available

  57. OLIVER-KRASINSKI JM, Bidot S, Ingram JW, O'Toole KM, et al
    Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
    Arch Pathol Lab Med. 2024;148:223-229.
    PubMed    
    Abstract available

  58. CHEN X, Yin Y, He Y, Meng F, et al
    The prognostic significance and clinical relevance of stem cell characteristic in bladder cancer.
    Heliyon. 2024;10:e24858.
    PubMed    
    Abstract available

  59. SONG Z, Gui S, Xiao S, Rao X, et al
    A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
    Sci Rep. 2024;14:3198.
    PubMed    
    Abstract available

  60. BAO R, Qu H, Li B, Cheng K, et al
    Bibliometric analysis of immunotherapy for bladder cancer: A correspondence.
    Hum Vaccin Immunother. 2024;20:2313287.
    PubMed    


  61. LIU K, Wang L, Peng J, Lyu Y, et al
    Drug-Loaded Bacillus Calmette-Guerin Bacteria for Immuno-Chemo Combo Therapy in Bladder Cancer.
    Adv Mater. 2024 Feb 8:e2310735. doi: 10.1002/adma.202310735.
    PubMed    
    Abstract available

  62. NINA NINA DG, Robeldo TA, Silva AD, Dos Santos Goncalves VS, et al
    [6]-Shogaol Induces Apoptosis of Murine Bladder Cancer Cells.
    Cell Physiol Biochem. 2024;58:49-62.
    PubMed    
    Abstract available

  63. CHANG KC, Hung SF
    Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e15.
    Urol Oncol. 2024 Feb 6:S1078-1439(24)00018-8. doi: 10.1016/j.urolonc.2024.
    PubMed    


  64. KOOL R, Dragomir A, Kulkarni GS, Marcq G, et al
    Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis.
    Eur Urol Oncol. 2024 Feb 6:S2588-9311(24)00040-3. doi: 10.1016/j.euo.2024.
    PubMed    
    Abstract available

  65. BUKAVINA L, Davis L, Helstrom E, Magee D, et al
    Population Estimates of Ovarian Cancer Risk in a Cohort of Patients with Bladder Cancer.
    Eur Urol Focus. 2024 Feb 6:S2405-4569(24)00015-4. doi: 10.1016/j.euf.2024.
    PubMed    
    Abstract available

  66. REIS H, Paner GP
    Glandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates.
    Adv Anat Pathol. 2024;31:88-95.
    PubMed    
    Abstract available

  67. LI J, Huang C, Xiong T, Zhuang C, et al
    Erratum: A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro: Erratum.
    Int J Biol Sci. 2024;20:1088-1089.
    PubMed    
    Abstract available

  68. AKAN S, Atmaca MC
    [Guillain-Barre syndrome caused by intravesical instillation of Bacillus Calmette-Guerin].
    Ideggyogy Sz. 2024;77.
    PubMed    
    Abstract available

  69. SONG J, Wu Y, Chen Z, Zhai D, et al
    Clinical significance of KRT7 in bladder cancer prognosis.
    Int J Biol Markers. 2024 Feb 6:3936155231224798. doi: 10.1177/03936155231224798.
    PubMed    
    Abstract available

  70. GUO CC, Lee S, Lee JG, Chen H, et al
    Molecular profile of bladder cancer progression to clinically aggressive subtypes.
    Nat Rev Urol. 2024 Feb 6. doi: 10.1038/s41585-023-00847.
    PubMed    
    Abstract available

  71. CHENG L, Wang C, Sun Q
    Teaching NeuroImage: Metastatic Urachal Carcinoma in the Extraocular Muscles Mimicking Oculomotor Paralysis.
    Neurology. 2024;102:e209191.
    PubMed    


  72. WANG J, Jiang Z, Wang K, Zheng Q, et al
    Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer.
    Aging (Albany NY). 2024;16.
    PubMed    
    Abstract available

  73. WANG W, Shan D, Wang G, Mao X, et al
    Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer.
    Cell Insight. 2024;3:100149.
    PubMed    
    Abstract available

  74. ZHOU H, Li R, Liu J, Long J, et al
    Characterization and verification of CAF-relevant prognostic gene signature to aid therapy in bladder cancer.
    Heliyon. 2024;10:e23873.
    PubMed    
    Abstract available

  75. TRECARTEN SJ, Svatek RS
    Supplementary selenium and vitamin E in non-muscle-invasive bladder cancer.
    Nat Rev Urol. 2024 Feb 5. doi: 10.1038/s41585-024-00859.
    PubMed    


  76. JIANG M, Chen R, Hu B, Xiong S, et al
    FATP2 activates PI3K/Akt/mTOR pathway by inhibiting ATF3 and promotes the occurrence and development of bladder cancer.
    Cell Signal. 2024;117:111087.
    PubMed    
    Abstract available

  77. ONDER RO, Aslan S, Bekci T
    Prevalence of Bladder Cancers Incidentally Detected During Multiparametric MRI Scans of the Prostate Gland and the Clinical Significance of Scoring Them According to VI-RADS: A Pictorial Single-Centre Study.
    J Belg Soc Radiol. 2024;108:7.
    PubMed    
    Abstract available

  78. MYERS AA, Kamat AM, Kilbert A, Galsky MD, et al
    Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel.
    J Immunother Cancer. 2024;12:e008508.
    PubMed    


  79. LUO Y, Li Q, Liao Z, Luo Z, et al
    Unusual case of retroperitoneal hematoma and duodenal ulcerative bleeding after nephrectomy: Case report.
    Medicine (Baltimore). 2024;103:e33765.
    PubMed    
    Abstract available

  80. KOSHIISHI H, Yoshimura T, Konno T, Fujie T, et al
    [A Case Report of Metachronous Multiple Cancers Including Triple Lung Cancers, Gastric Cancer, and Double Urothelial Cancers].
    Gan To Kagaku Ryoho. 2023;50:1656-1658.
    PubMed    
    Abstract available

  81. YOU X, Zhu C, Yu P, Wang X, et al
    Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
    Biomed Pharmacother. 2024;171:116152.
    PubMed    
    Abstract available

  82. KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
    Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
    PubMed    
    Abstract available

  83. TRIPATHI N, Fortuna GG, Gebrael G, Dal E, et al
    Predictors of response to neoadjuvant therapy in urothelial cancer.
    Crit Rev Oncol Hematol. 2024;194:104236.
    PubMed    
    Abstract available

  84. AN L, Dong K, Chi S, Wei S, et al
    lncRNA UCA1 promotes tumor progression by targeting SMARCD3 in cervical cancer.
    Mol Carcinog. 2023 Dec 20. doi: 10.1002/mc.23659.
    PubMed    
    Abstract available

  85. URSO L, Bauckneht M, Albano D, Chondrogiannis S, et al
    The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
    Expert Rev Med Devices. 2024;21.
    PubMed    
    Abstract available

  86. ZHAO J, Guo CC, Rao P
    Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract.
    Adv Anat Pathol. 2024;31:80-87.
    PubMed    
    Abstract available

  87. LARKINS MC, Pasli M, Bhatt A, Burke A, et al
    Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy.
    J Surg Oncol. 2024;129:649-658.
    PubMed    
    Abstract available

  88. MATSUE T, Kato M, Kosugi Y, Ishizaki K, et al
    Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.
    Jpn J Clin Oncol. 2024;54:182-191.
    PubMed    
    Abstract available

  89. ARSHIA A, Hassan FA, Hensley PJ, Allison DB, et al
    Urinary tract cytology showing variant morphology and divergent differentiation.
    Cytopathology. 2024;35:199-212.
    PubMed    
    Abstract available

  90. KHAJIR G, Sun T, Wang H, Sprenkle PC, et al
    Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up.
    Cytopathology. 2024;35:235-241.
    PubMed    
    Abstract available

  91. YAMAMOTO S, Kato M, Matsue T, Yukimatsu N, et al
    Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
    Jpn J Clin Oncol. 2024;54:221-224.
    PubMed    
    Abstract available

  92. MA G, Jia H, Zhang G, Liang Y, et al
    Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder.
    Oncologist. 2024;29:e248-e258.
    PubMed    
    Abstract available

  93. HORIKIRIZONO H, Nakaichi M, Itoh H, Itamoto K, et al
    Intraoperative hypertensive crisis in a dog with functional paraganglioma of the gall bladder.
    J Small Anim Pract. 2024;65:144-148.
    PubMed    
    Abstract available

  94. YE J, Liao X, Qiu Y, Wei Q, et al
    A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.
    Tumori. 2024;110:25-33.
    PubMed    
    Abstract available

  95. PIETZAK EJ, Herr HW
    An Interleukin-15 Superagonist with BCG - A Major Therapeutic Advancement or Just a Small Step in the Right Direction?
    NEJM Evid. 2023;2:EVIDe2200264.
    PubMed    
    Abstract available

  96. CHAMIE K, Chang SS, Kramolowsky E, Gonzalgo ML, et al
    IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    NEJM Evid. 2023;2:EVIDoa2200167.
    PubMed    
    Abstract available

  97. DJUG H, Hasukic S, Jagodic S, Ivanic D, et al
    Adjuvant Intravesical Chemotherapy Versus Immunotherapy for All Risk Groups of Patients With Non-muscle Invasive Bladder Cancer.
    Med Arch. 2023;77:460-464.
    PubMed    
    Abstract available

  98. RAHMAN ZA, Hidayatullah F, Lim J, Hakim L, et al
    A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
    Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12154.
    PubMed    
    Abstract available

  99. PRONTERA PP, Prusciano FR, Lattarulo M, Utano E, et al
    Quality of bladder cancer treatment information on YouTube: May the user's profile affect the quality of results?
    Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12179.
    PubMed    
    Abstract available

  100. BRETON-PATIENT C, Billotte S, Duchambon P, Fontaine G, et al
    Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in Bladder Cancer.
    Chembiochem. 2024 Feb 16:e202300855. doi: 10.1002/cbic.202300855.
    PubMed    
    Abstract available

  101. MAIMON Y, Amiel G, Cohen Z, Hoffman A, et al
    Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study.
    Integr Cancer Ther. 2024;23:15347354241233233.
    PubMed    
    Abstract available

  102. CAO B, Li Q, Xu P, Zhang Y, et al
    Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging biomarker combined with a decision-tree mode to preoperatively predict the pathological grade of bladder cancer.
    Clin Radiol. 2024 Feb 9:S0009-9260(24)00082-5. doi: 10.1016/j.crad.2024.
    PubMed    
    Abstract available

  103. KATIMS AB, Tallman J, Vertosick E, Porwal S, et al
    Response to 2 Induction Courses of Bacillus Calmette-Guerin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.
    JAMA Oncol. 2024 Feb 15. doi: 10.1001/jamaoncol.2023.6804.
    PubMed    
    Abstract available

  104. CHENNIAPPAN A, Stephen NS, Srinivas BH, Sreenivasan SK, et al
    Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with unusual site of metastasis with grim outcome.
    Indian J Pathol Microbiol. 2024;67:175-177.
    PubMed    
    Abstract available

  105. GUPTA RK, Wasnik P, Sharma AR
    Papillary urothelial neoplasm of low malignant potential with osseous metaplasia in a 19-year-old chronic smoker: A case report with review of literature.
    Indian J Pathol Microbiol. 2024;67:159-161.
    PubMed    
    Abstract available

  106. SU Y, Chen L, Yang J
    Hesperetin Inhibits Bladder Cancer Cell Proliferation and Promotes Apoptosis and Cycle Arrest by PI3K/AKT/FoxO3a and ER Stress-mitochondria Pathways.
    Curr Med Chem. 2024 Feb 13. doi: 10.2174/0109298673283888231217174702.
    PubMed    
    Abstract available

  107. PAN G, Xie H, Xia Y
    Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Heliyon. 2024;10:e25573.
    PubMed    
    Abstract available

  108. RIJNDERS M, Nakauma-Gonzalez JA, Robbrecht DGJ, Gil-Jimenez A, et al
    Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
    Nat Commun. 2024;15:1349.
    PubMed    
    Abstract available

  109. AMARA CS, Kami Reddy KR, Yuntao Y, Chan YS, et al
    The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
    Nat Commun. 2024;15:1373.
    PubMed    
    Abstract available

  110. ALI M, Koo K, Chang D, Chan P, et al
    Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
    Radiat Oncol. 2024;19:23.
    PubMed    
    Abstract available

  111. SUZUKI A, Ito H, Uemura K, Muraoka K, et al
    Surgical proficiency in laparoscopic radical cystectomy with extracorporeal urinary diversion and its adequacy for the execution of robot-assisted radical cystectomy with intracorporeal urinary diversion.
    Asian J Endosc Surg. 2024;17:e13289.
    PubMed    
    Abstract available

  112. LI C, Qin W, Hu J, Lin J, et al
    A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer.
    Biochem Genet. 2024 Feb 14. doi: 10.1007/s10528-024-10683.
    PubMed    
    Abstract available

  113. ORTNER G, Guven S, Somani BK, Nicklas A, et al
    Experts' recommendations in laser use for the treatment of bladder cancer: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training and Research in Urological Surgery and Technology (TRUST)-Group.
    World J Urol. 2024;42:79.
    PubMed    
    Abstract available

  114. LUO S, Huang X, Li S, Chen Y, et al
    Homogeneous Polyporus polysaccharide exerts anti-bladder cancer effects via autophagy induction.
    Pharm Biol. 2024;62:214-221.
    PubMed    
    Abstract available

  115. SHISHKOV DD, Shishkov DG, Todorov S, Mihaylov N, et al
    Laparoscopic vs. open surgical access radical cystectomy with subsequent orthotopic reconstruction in the treatment of invasive urothelial carcinoma of the bladder.
    Folia Med (Plovdiv). 2023;65:894-901.
    PubMed    
    Abstract available

  116. SILVA IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, et al
    Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management.
    Gene. 2024;907:148252.
    PubMed    
    Abstract available

  117. WEI Z, Xv Y, Liu H, Li Y, et al
    A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study.
    Int J Surg. 2024 Feb 13. doi: 10.1097/JS9.0000000000001194.
    PubMed    
    Abstract available

  118. LEE CU, Lee JH, Lee HW, Chung JH, et al
    Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
    Sci Rep. 2024;14:3497.
    PubMed    
    Abstract available

  119. XU Y, Sun G, Yang T, Li H, et al
    Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model.
    Int J Hyperthermia. 2024;41:2316085.
    PubMed    
    Abstract available

  120. LOPEZ-BELTRAN A, Cookson MS, Guercio BJ, Cheng L, et al
    Advances in diagnosis and treatment of bladder cancer.
    BMJ. 2024;384:e076743.
    PubMed    
    Abstract available

  121. SU Y, Chen L, Yang J
    Network pharmacology and in vitro experiments reveal sophoridine-induced apoptosis and G(1) phase arrest via ROS-dependent PI3K/Akt/FoxO3a pathway activation in human bladder cancer cells.
    Chem Biol Drug Des. 2024;103:e14476.
    PubMed    
    Abstract available

  122. LIEDBERG F, Hagberg O, Aljabery F, Falini V, et al
    [Radical cystectomy for bladder cancer is a complex procedure].
    Lakartidningen. 2024;121:23132.
    PubMed    
    Abstract available

  123. CETIN T, Bolat D, Cesur G, Erdemoglu O, et al
    Comparison of Monopolar Versus Bipolar Repeat Transurethral Resection of Bladder Tumours.
    J Coll Physicians Surg Pak. 2024;34:230-234.
    PubMed    
    Abstract available

  124. XIE T, Peng S, Liu S, Zheng M, et al
    Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
    Mol Cancer. 2024;23:30.
    PubMed    
    Abstract available

  125. MATHEW THOMAS V, Grivas P, Agarwal N
    Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
    Med. 2024;5:109-111.
    PubMed    
    Abstract available

  126. LU Q, Wang J, Tao Y, Zhong J, et al
    Small Cajal Body-Specific RNA12 Promotes Carcinogenesis through Modulating Extracellular Matrix Signaling in Bladder Cancer.
    Cancers (Basel). 2024;16:483.
    PubMed    
    Abstract available

  127. LI AH, Park SY, Li P, Zhou C, et al
    Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.
    Int J Mol Sci. 2024;25:1783.
    PubMed    
    Abstract available

  128. KUSTRIMOVIC N, Bilato G, Mortara L, Baci D, et al
    The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.
    Int J Mol Sci. 2024;25:1732.
    PubMed    
    Abstract available

  129. GILL E, Perks CM
    Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.
    Int J Mol Sci. 2024;25:1557.
    PubMed    
    Abstract available

  130. FAN LW, Li YR, Wu CM, Chuang KT, et al
    Inpatient Outcomes of Patients Undergoing Robot-Assisted versus Laparoscopic Radical Cystectomy for Bladder Cancer: A National Inpatient Sample Database Study.
    J Clin Med. 2024;13:772.
    PubMed    
    Abstract available

  131. TANG R, Wang H, Liu J, Song L, et al
    TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Eur J Med Res. 2024;29:112.
    PubMed    
    Abstract available

  132. IBRAHIM M, Rabinowitz J, Hilbert R, Ghose A, et al
    The role of URO17(R) in diagnosis and follow up of bladder cancer patients.
    BMC Urol. 2024;24:34.
    PubMed    
    Abstract available

  133. KAWADA T, Yanagisawa T, Rajwa P, Motlagh RS, et al
    The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2024 Jan 17:S1558-7673(24)00009.
    PubMed    
    Abstract available

  134. HUANG SY, Su PJ, Lin CT, Kuo MC, et al
    The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis.
    Cancer Med. 2024;13:e7008.
    PubMed    
    Abstract available


  135. [Not Available].
    Aktuelle Urol. 2024;55:24-25.
    PubMed    



  136. [Not Available].
    Aktuelle Urol. 2024;55:22-23.
    PubMed    



  137. [Not Available].
    Aktuelle Urol. 2024;55:18-20.
    PubMed    


  138. NGUYEN NJ, Sherman C, van der Kwast TH, Downes MR, et al
    Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Pathol Res Pract. 2024;254:155105.
    PubMed    
    Abstract available

  139. KARAHAN I, Bilgin B
    Is my patient with urothelial cancer (in)eligible for platinum?
    Urol Oncol. 2024;42:27.
    PubMed    


  140. ZHU X, Koshkin VS
    Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Med. 2024;5:106-108.
    PubMed    
    Abstract available

  141. TAUZIEDE-ESPARIAT A, Masliah-Planchon J, Tran S, Filser M, et al
    Brain metastasis of a urothelial neuroendocrine carcinoma: A double pitfall for neuropathologists and DNA-methylation profiling.
    Neuropathol Appl Neurobiol. 2024;50:e12951.
    PubMed    


  142. TAMURA D, Abe M, Hiraki H, Sasaki N, et al
    Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
    Cancer Sci. 2024;115:529-539.
    PubMed    
    Abstract available

  143. GWAK CH, Suh J, Lim B, Song C, et al
    Preoperative C-reactive protein to albumin ratio as a novel prognostic biomarker for the oncological outcomes of radical nephroureterectomy.
    Urol Oncol. 2024;42:30.
    PubMed    
    Abstract available

  144. CARMONA O, Kleinmann N, Zilberman DE, Dotan ZA, et al
    Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma?
    Clin Genitourin Cancer. 2024;22:98-105.
    PubMed    
    Abstract available

  145. FILIPPI L, Schillaci O
    NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
    Expert Rev Anticancer Ther. 2024;24.
    PubMed    
    Abstract available

  146. SONPAVDE GP, Subbiah V
    Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.
    Ann Oncol. 2024;35:150-153.
    PubMed    


  147. NECCHI A, Pouessel D, Leibowitz R, Gupta S, et al
    Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
    Ann Oncol. 2024;35:200-210.
    PubMed    
    Abstract available

  148. LI M, Yan X, Liu H, Miao W, et al
    Novel MSH2 and TSC2 variants in a Chinese family with Lynch syndrome and their synergistic impact in urothelial carcinoma.
    Transl Res. 2024;265:26-35.
    PubMed    
    Abstract available

  149. WEI Y, Zhao M, He T, Chen N, et al
    Quantitatively Lighting up the Spatial Organization of CD47/SIRPalpha Immune Checkpoints on the Cellular Membrane with Single-Molecule Localization Microscopy.
    ACS Nano. 2023;17:21626-21638.
    PubMed    
    Abstract available

  150. VOS N, Minner J, Bohm J
    [Paraganglioma of the urinary bladder-a rare, but relevant differential diagnosis].
    Urologie. 2024;63:168-170.
    PubMed    
    Abstract available

  151. LUO S, Wu Y, Yang R, Huang G, et al
    Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC.
    Urol Oncol. 2024;42:30.
    PubMed    
    Abstract available

  152. YILMAZ H, Teke K, Suer E, Izol V, et al
    Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular invasion in survival after radical cystectomy?
    Urol Oncol. 2024;42:30.
    PubMed    
    Abstract available

  153. MATHAVAN A, Mathavan A, Murillo-Alvarez R, Gera K, et al
    Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies.
    Clin Genitourin Cancer. 2024;22:67-75.
    PubMed    


  154. RAC G, Patel HD, James C, Desai S, et al
    Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.
    Mol Oncol. 2024;18:291-304.
    PubMed    
    Abstract available

  155. GURNEY H, Clay TD, Oliveira N, Wong S, et al
    Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia.
    Asia Pac J Clin Oncol. 2023;19:585-595.
    PubMed    
    Abstract available

  156. NECCHI A, Faltas BM, Slovin SF, Meeks JJ, et al
    Immunotherapy in the Treatment of Localized Genitourinary Cancers.
    JAMA Oncol. 2023;9:1447-1454.
    PubMed    
    Abstract available

  157. SOTELO M, Munoz-Unceta N, Matorras A, Jara P, et al
    Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution.
    Clin Transl Oncol. 2024;26:682-688.
    PubMed    
    Abstract available

  158. JOYCE DD, Shan Y, Stewart CA, Chamie K, et al
    A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:14-22.
    PubMed    
    Abstract available

  159. PARK K, Lee HJ, Kim TU, Ryu H, et al
    Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Asia Pac J Clin Oncol. 2023;19:739-746.
    PubMed    
    Abstract available

  160. TAN KL, Viswambaram P, McCombie S, Moe A, et al
    Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette-Guerin.
    Asia Pac J Clin Oncol. 2023;19:697-705.
    PubMed    
    Abstract available

  161. ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
    Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG).
    Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323609.
    PubMed    
    Abstract available

  162. PROIETTI F, Flammia RS, Licari LC, Bologna E, et al
    Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience.
    J Pers Med. 2024;14:212.
    PubMed    
    Abstract available

  163. LIDAGOSTER S, Ben-David R, De Leon B, Sfakianos JP, et al
    BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.
    Curr Oncol. 2024;31:1063-1078.
    PubMed    
    Abstract available

  164. TUFANO A, Rosati D, Moriconi M, Santarelli V, et al
    Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.
    Curr Oncol. 2024;31:818-827.
    PubMed    
    Abstract available

  165. XU H, Sun D, Zhou D, Sun S, et al
    Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer.
    Cancer Invest. 2024 Feb 23:1-13. doi: 10.1080/07357907.2024.2308161.
    PubMed    
    Abstract available

  166. ATES SG, Demirel BB, Basar H, Ucmak G, et al
    The Added-value of Staging (18)F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.
    Mol Imaging Radionucl Ther. 2024;33:11-18.
    PubMed    
    Abstract available

  167. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Shun-Fa Hung's Letter to the editor regarding the article "Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer".
    Urol Oncol. 2024 Feb 21:S1078-1439(24)00021.
    PubMed    


  168. BEATRICI E, Labban M, Filipas DK, Stone BV, et al
    Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.
    Int Braz J Urol. 2024;50:199-208.
    PubMed    
    Abstract available

  169. WANG X, Song D, Zhu B, Jin Y, et al
    Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer.
    Anticancer Drugs. 2024 Feb 23. doi: 10.1097/CAD.0000000000001571.
    PubMed    
    Abstract available

  170. YU H, Zhuang J, Zhou Z, Song Q, et al
    METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway.
    Int J Biol Sci. 2024;20:1471-1491.
    PubMed    
    Abstract available

  171. DU W, Tu S, Zhang W, Zhang Y, et al
    UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT.
    Int J Biol Sci. 2024;20:1389-1409.
    PubMed    
    Abstract available

  172. FALABELLA R, La Falce S, Ponti FC, Di Fino G, et al
    A rare case of muscle invasive bladder cancer in a Vescical inguinal hernia.
    Urol Case Rep. 2024;53:102673.
    PubMed    
    Abstract available

  173. SAAD R, Ghaddar A, Zeenny RM
    Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
    J Med Case Rep. 2024;18:107.
    PubMed    
    Abstract available

  174. YUAN H, Wang T, Peng P, Xu Z, et al
    Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment.
    Clin Genitourin Cancer. 2024 Jan 22:S1558-7673(24)00012.
    PubMed    
    Abstract available

  175. WANG X, Wang L
    Research progress of ICIS in the treatment of bladder cancer.
    Panminerva Med. 2024 Feb 21. doi: 10.23736/S0031-0808.24.05102.
    PubMed    


  176. QI D, Lu Y, Qu H, Dong Y, et al
    Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature.
    iScience. 2024;27:109138.
    PubMed    
    Abstract available

  177. KANG NW, Feng YH, Lin KL, Chen YC, et al
    Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Cancer Med. 2024;13:e6972.
    PubMed    
    Abstract available

  178. OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
    Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2024 Feb 20. doi: 10.1245/s10434-024-15009.
    PubMed    
    Abstract available

  179. ISALI I, Helstrom EK, Uzzo N, Lakshmanan A, et al
    Current Trends and Challenges of Microbiome Research in Bladder Cancer.
    Curr Oncol Rep. 2024 Feb 20. doi: 10.1007/s11912-024-01508.
    PubMed    
    Abstract available

  180. RAJA D, Singh A, Kurra S, Nayak B, et al
    Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
    Med Oncol. 2024;41:74.
    PubMed    
    Abstract available

  181. FAN N, Zhang L, Wang Z, Ding H, et al
    Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.
    Anticancer Agents Med Chem. 2024;24:348-357.
    PubMed    
    Abstract available

  182. HAN X, Gao K, Shang L, Wei L, et al
    Caregiver experiences of caring for family members with urostomy: a qualitative study.
    Support Care Cancer. 2024;32:167.
    PubMed    
    Abstract available

  183. ZHANG S, Lin T, Xiong X, Chen C, et al
    Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence.
    Nat Rev Urol. 2024 Feb 19. doi: 10.1038/s41585-024-00857.
    PubMed    
    Abstract available

  184. YAO Q, Jiang H, Niu H, Hu G, et al
    Prospective learning curve analysis of en bloc resection of bladder tumor using an ex vivo porcine model.
    BMC Surg. 2024;24:65.
    PubMed    
    Abstract available

  185. LI Q, Su X, Qing L, Xu W, et al
    HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
    Arch Esp Urol. 2024;77:79-91.
    PubMed    
    Abstract available

  186. LIN R, Fu X, Huang J
    Relationship between Changes of Serum Vascular Endothelial Growth Factor and Folate Receptor-alpha Levels and Clinical Efficacy of Toripalimab in Patients with Bladder Cancer.
    Arch Esp Urol. 2024;77:31-37.
    PubMed    
    Abstract available

  187. HARSANYI S, Kianickova K, Katrlik J, Danisovic L, et al
    Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.
    J Cancer Res Clin Oncol. 2024;150:96.
    PubMed    
    Abstract available

  188. RT R, Sharma A, Biswal D, Goel S, et al
    Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer.
    Urologia. 2024 Feb 19:3915603241232115. doi: 10.1177/03915603241232115.
    PubMed    
    Abstract available

  189. ABUHASANEIN S, Jahnson S, Kjolhede H
    Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics.
    BJUI Compass. 2023;5:261-268.
    PubMed    
    Abstract available

  190. MIYAKE M, Kitamura H, Nishimura N, Miyamoto T, et al
    Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
    BJUI Compass. 2023;5:269-280.
    PubMed    
    Abstract available

  191. ZHOU Q, Fang L, Tang Y, Wang Q, et al
    Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer.
    J Cancer. 2024;15:1770-1778.
    PubMed    
    Abstract available

  192. YU L, Lin N, Ye Y, Zhou S, et al
    Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance.
    J Cancer. 2024;15:1734-1749.
    PubMed    
    Abstract available

  193. TAN Z, Chen X, Li H, Huang Y, et al
    HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study.
    J Cancer. 2024;15:1624-1641.
    PubMed    
    Abstract available

  194. LV H, Zhou X, Liu Y, Liu Y, et al
    Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer.
    Discov Oncol. 2024;15:40.
    PubMed    
    Abstract available

  195. LIU S, Wang X, Sun X, Wei B, et al
    Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1.
    Phytomedicine. 2024;126:155426.
    PubMed    
    Abstract available

  196. XIE S, Friesen MC, Baris D, Schwenn M, et al
    Occupational exposure to organic solvents and risk of bladder cancer.
    J Expo Sci Environ Epidemiol. 2024 Feb 16. doi: 10.1038/s41370-024-00651.
    PubMed    
    Abstract available

  197. LI T, Huang M, Sun N, Hua X, et al
    Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
    J Exp Clin Cancer Res. 2024;43:50.
    PubMed    
    Abstract available

  198. SHAO B, Wu K, Wan S, Sun P, et al
    Prediction of future research trends in bladder urothelial carcinoma: Bibliometric analysis.
    Medicine (Baltimore). 2024;103:e37176.
    PubMed    
    Abstract available

  199. BODDU VK, Zamzow P, Kramer MW, Merseburger AS, et al
    Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
    Cell Commun Signal. 2024;22:129.
    PubMed    
    Abstract available

  200. YIP W, Assel MJ, Wong NC, Tracey AT, et al
    Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience.
    Urol Pract. 2024;11:356-366.
    PubMed    
    Abstract available

  201. BERG SA, McGregor BA
    One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
    Curr Treat Options Oncol. 2024;25:206-219.
    PubMed    
    Abstract available

  202. DONG Y, Wu X, Xu C, Hameed Y, et al
    Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
    Aging (Albany NY). 2024;16:2591-2616.
    PubMed    
    Abstract available

  203. GALSKY MD, Guan X, Rishipathak D, Rapaport AS, et al
    Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
    Cell Rep Med. 2024;5:101393.
    PubMed    
    Abstract available

  204. PALIOGIANNIS P, Lobrano R, Bella MA, Fara A, et al
    PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Ann Diagn Pathol. 2024;69:152267.
    PubMed    
    Abstract available

  205. NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
    Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
    J Pharm Biomed Anal. 2024;240:115966.
    PubMed    
    Abstract available

  206. ZHANG T, Li H, Lin C, An R, et al
    Effects of an intraoperative intravenous Bolus Dose of Dexmedetomidine on postoperative catheter-related bladder discomfort in male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial.
    Eur J Clin Pharmacol. 2024;80:465-474.
    PubMed    
    Abstract available

  207. CAN O, Danis E, Kutluturk EG, Polat EC, et al
    Hybrid technique has lower stricture rates than Wallace and Bricker.
    Surg Oncol. 2024;52:102036.
    PubMed    
    Abstract available

  208. RAGI N, Walmsley SJ, Jacobs FC, Rosenquist TA, et al
    Screening DNA Damage in the Rat Kidney and Liver by Untargeted DNA Adductomics.
    Chem Res Toxicol. 2024;37:340-360.
    PubMed    
    Abstract available

  209. TOSI G, Barnes JR
    Early-Onset Asymptomatic Polypoid Cystitis in Two Adolescent Male Beagle Dogs.
    Toxicol Pathol. 2023;51:357-360.
    PubMed    
    Abstract available

  210. STORMOEN DR, Joensen UN, Daugaard G, Oturai P, et al
    Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.
    Int J Clin Oncol. 2024;29:309-317.
    PubMed    
    Abstract available

  211. NAMUGOSA M, Matthew AN, Fogg R, Klausner AP, et al
    Characterization of Cystoscopy Performance and Reporting Practices at Academic Urology Centers.
    Urol Pract. 2024;11:249-253.
    PubMed    


  212. BURALLI R, Ribeiro A, Cremonese C, Vineis P, et al
    Cancer mortality and premature deaths among hairdressers in Brazil.
    Environ Res. 2024;244:117942.
    PubMed    
    Abstract available

  213. CHEN Y, Liao Y, Yang Y, Zheng X, et al
    Letter to the editor: Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2024;110:1289-1290.
    PubMed    


  214. HUANG J, Chen G, Liu H, Jiang W, et al
    MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.
    Eur Radiol. 2024;34:1804-1815.
    PubMed    
    Abstract available

  215. BOTROUS S, Elmaghraby A, El-Achy S, Mustafa Y, et al
    Inhibition of TNF-alpha Oncogene Expression by Artemisia Annua L. Extract Against Pioglitazone Side Effects in Male Albino Mice.
    Mol Biotechnol. 2024;66:432-441.
    PubMed    
    Abstract available

  216. SUTO H, Inui Y, Nishikawa S, Okamura A, et al
    Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease.
    J Cancer Res Ther. 2023;19.
    PubMed    
    Abstract available

  217. DURUR S, Uzun H, Bedir R, Nalkiran I, et al
    Prognostic importance of PD-L1 expression in bladder cancer patients.
    J Cancer Res Ther. 2023;19.
    PubMed    
    Abstract available

  218. ONER M, Lin E, Chiu KY, Chen MC, et al
    p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
    Anticancer Res. 2024;44:543-553.
    PubMed    
    Abstract available

  219. LU SM, Zhang Y, Dong XT, Wang JL, et al
    Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
    BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
    PubMed    


  220. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    PubMed    
    Abstract available

  221. ZHANG L, Zhang R, Jin D, Zhang T, et al
    Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
    Br J Cancer. 2024 Feb 8. doi: 10.1038/s41416-024-02598.
    PubMed    
    Abstract available

  222. FONT A, Mellado B, Climent MA, Virizuela JA, et al
    Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
    Br J Cancer. 2024;130:434-441.
    PubMed    
    Abstract available

  223. NIERENGARTEN MB
    Major advancements in first-line treatments for advanced urothelial cancer.
    Cancer. 2024;130:333-334.
    PubMed    


  224. PAN J, Xie X, Sheng J, Ju C, et al
    Construction and identification of lncRNA/circRNA-coregulated ceRNA networks in gemcitabine-resistant bladder carcinoma.
    Carcinogenesis. 2023;44:847-858.
    PubMed    
    Abstract available

  225. BINHUMAID FS, Goel A, Gordon NS, Abbotts B, et al
    Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.
    Eur Urol. 2024 Jan 31:S0302-2838(24)00017-4. doi: 10.1016/j.eururo.2024.
    PubMed    


  226. SHARIAT SF, Laukhtina E
    Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
    Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
    PubMed    


  227. FENG YN, Xie GY, Xiao L
    Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
    Eur Urol. 2023;84:e145.
    PubMed    


  228. PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
    Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
    Eur Urol. 2023;84:e154.
    PubMed    


  229. LI DX, Feng DC, Deng S
    Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
    Eur Urol. 2023;84:e152-e153.
    PubMed    


  230. MOSCHINI M, Necchi A, Montorsi F
    Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  231. KONDO T
    Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:133.
    PubMed    


  232. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
    Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:125-132.
    PubMed    
    Abstract available

  233. BRISUDA A, Hornak J, Zemlickova B, Hacek J, et al
    Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Int Urol Nephrol. 2024 Feb 8. doi: 10.1007/s11255-023-03924.
    PubMed    
    Abstract available

  234. LI Y, Xu H, Lin T, Zhang J, et al
    Preoperative low plasma creatine kinase levels predict worse survival outcomes in bladder cancer after radical cystectomy.
    Int Urol Nephrol. 2024 Feb 5. doi: 10.1007/s11255-024-03957.
    PubMed    
    Abstract available

  235. KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
    Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
    PubMed    
    Abstract available

  236. ZHAI H, Wang Y, Chen Z, Wang Z, et al
    Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
    Int Urol Nephrol. 2024;56:941-955.
    PubMed    
    Abstract available

  237. MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
    Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
    Int Urol Nephrol. 2024;56:965-972.
    PubMed    
    Abstract available

  238. KAY H, Matulewicz RS, Bjurlin MA
    Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
    J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
    PubMed    


  239. MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
    Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
    J Urol. 2024;211:482-483.
    PubMed    


  240. GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
    Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
    J Urol. 2024;211:476-480.
    PubMed    


  241. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    PubMed    


  242. BANEK S, Hoeh B, Cano Garcia C, Koll F, et al
    Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies.
    Urol Int. 2024;108:1-8.
    PubMed    
    Abstract available

  243. VOLZ Y, Trappmann R, Ebner B, Eismann L, et al
    Upstaging after Transurethral Resection of the Bladder for Non-Muscle-Invasive Cancer of the Bladder: Who Is at Highest Risk?
    Urol Int. 2024;108:42-48.
    PubMed    
    Abstract available

  244. MORRIS KE, Pappas TN
    Malignancy in the public life: the story of Hubert Humphrey's bladder cancer.
    Urology. 2024 Jan 31:S0090-4295(24)00017-7. doi: 10.1016/j.urology.2023.
    PubMed    


  245. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    PubMed    
    Abstract available

  246. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    PubMed    
    Abstract available

  247. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    PubMed    
    Abstract available

  248. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    PubMed    
    Abstract available

  249. KVIKSTAD V, Lillesand M, Gudlaugsson E, Mangrud OM, et al
    Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
    PLoS One. 2024;19:e0297141.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;